Seasonal malaria chemoprevention (SMC) is recommended by the World Health Organization for the prevention of malaria in areas of highly seasonal transmission. SMC employs a regimen of sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ), known as SPAQ. However, resistance to SPAQ may compromise its effectiveness against clinical malaria in children. This study examines resistance marker prevalence before and after one annual SMC round in Mozambique, where resistance has been observed, to improve understanding of the impact of resistance on SMC effectiveness. The study is part of a larger implementation study that involved SMC delivery to 72,000 children in Malema and Mecubúri districts of Nampula province, northern Mozambique, as well as Lalaua district, a control area where SMC was not implemented.
This poster was presented at the 72nd annual meeting of the American Society of Tropical Medicine and Hygiene.
« Back to Publications